湖南启元律师事务所 关于湖南尔康制药股份有限公司 湖南启元律师事务所 关于湖南尔康制药股份有限公司 2025年第一次临时股东大会的 法律意见书 二0二五年十一月 2025 年第一次临时股东大会的法律意见书 致：湖南尔康制药股份有限公司 湖南启元律师事务所接受湖南尔康制药股份有限公司（以下简称"公司"） 的委托，指派律师出席了公司 2025 年第一次临时股东大会（以下简称"本次股 东大会"），对会议进行现场律师见证，并出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》等法律、法 规和规范性文件以及《湖南尔康制药股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 本所律师出具本法律意见书基于公司已作出如下承诺：所有提供给本所律师 的文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠。 为出具本法律意见书，我们依法审核了公司提供的下列资料： 1 、 公 司 于 2025 年 10 月 30 日 发 布 在 深 圳 证 券 交 易 所 网 站 （http://ww ...

湖南尔康制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、召集人：公司董事会 证券代码：300267 证券简称：尔康制药 公告编号：2025-041 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 2、召开方式：现场投票与网络投票相结合的方式 3、召开时间： 现场会议时间：2025 年 11 月 14 日（星期五）下午 14：30 网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 14 日上午 09:15-09:25、09:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 14 日 9:15--15:00 期间的任意时间。 4、股权登记日：2025 年 11 月 10 日（星期一） 5、现场会议召开地点：公司会议室（湖南省长沙市浏阳工业园北园开元大 道工业路一号湖南尔康制药股份有限公司会议室） 6、 ...

湖南尔康制药股份有限公司 关于董事会换届完成并聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300267 证券简称：尔康制药 公告编号：2025-043 湖南尔康制药股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日召 开职工代表大会，选举了第六届董事会职工代表董事，并于 2025 年 11 月 14 日 召开 2025 年第一次临时股东大会，选举了第六届董事会董事。 2025 年 11 月 14 日，公司召开第六届董事会第一次会议，会议选举了董事 长、董事会专门委员会成员，聘任了高级管理人员、董事会秘书、证券事务代表； 截至本公告日，公司董事会换届选举已完成，高级管理人员聘任也已完成。现将 相关情况说明如下： 一、第六届董事会组成情况 董事长：帅放文 非独立董事：帅放文、孙庆荣、施湘燕、赵寻（职工代表董事） 独立董事：谭雪、柳铁蕃、吴勇 董事会各专门委员会： | 名称 | 主任委员 | 成员 | | --- | --- | --- | | 战略与发展委员会 | 帅放文 | 帅放文、孙庆荣、施湘燕、赵寻、柳 ...

帅放文先生的简历详见公司于 2025 年 10 月 30 日在巨潮资讯网披露的《关 于董事会换届选举的公告》（编号：2025-031）。 表决结果：同意票 7 票；反对票 0 票；弃权票 0 票。 二、审议通过了《关于选举第六届董事会专门委员会成员的议案》 证券代码：300267 证券简称：尔康制药 公告编号：2025-042 湖南尔康制药股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第六届董事会第一次会议 于 2025 年 11 月 14 日在公司会议室以现场结合通讯表决的方式召开。本次会议 以临时会议方式召开，会议通知的时间要求已经第六届董事会全体董事同意豁免。 本次会议由公司董事长帅放文先生主持，会议应参与表决的董事 7 名，实际参与 表决的董事 7 名，本次会议的通知、召开以及参与人数均符合相关法律、法规及 《公司章程》的有关规定。 经全体董事认真审议，形成如下决议： 一、审议通过了《关于选举第六届董事会董事长的议案》 根据《公司法》《公司章程》的有关规定，公司 ...

Core Points - The company announced the election of Zhao Xun as the employee representative director of the sixth board of directors during the employee representative meeting held on November 12, 2025 [1] Summary by Category - **Company Announcement** - The company held an employee representative meeting on November 12, 2025, where Zhao Xun was elected as the employee representative director [1]

证券代码：300267 证券简称：尔康制药 公告编号：2025-040 湖南尔康制药股份有限公司 关于选举第六届董事会职工代表董事的公告 附件： 赵寻女士将与公司 2025 年第一次临时股东大会选举产生的 3 名非独立董事 及 3 名独立董事共同组成公司第六届董事会，任期自第六届董事会组成之日起三 年。 赵寻女士符合《公司法》《上市公司章程指引》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等规定的有关职工代表董事 任职资格和条件。其担任公司职工代表董事后，公司第六届董事会中兼任公司高 级管理人员的董事以及由职工代表担任的董事人数总计未超过董事总数的二分 之一，符合相关法律法规的要求。 特此公告！ 湖南尔康制药股份有限公司 董 事 会 二〇二五年十一月十二日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《公司法》《上市公司章程指引》等有关规定，湖南尔康制药股份有限 公司（以下简称"公司"）于 2025 年 11 月 12 日召开职工代表大会，经与会职 工代表审议，会议选举赵寻女士（简历见附件）为公司第六届董事会职工代表董 ...

Core Viewpoint - The A-share market has seen a significant rise in flu-related stocks due to a noticeable increase in flu activity across China, with most provinces entering the flu epidemic period [1] Group 1: Stock Performance - Hendi Pharmaceutical has increased by over 14%, while Hualan Biological has risen by 11% [1] - Other notable performers include Peking University Pharmaceutical with a 10% increase, and Jinshi Yao with a rise of over 7% [1] - Several companies, including Teva Pharmaceutical, Erkang Pharmaceutical, and others, have also shown gains of over 5% [1] Group 2: Market Context - Recent data from the China CDC indicates that flu virus cases have surpassed other respiratory viruses, marking a significant shift in the current flu season [1] - Since mid-October, sales of related medications, such as Oseltamivir, have increased, with production running continuously [1]

Core Viewpoint - The company Erkang Pharmaceutical has announced its subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., is focusing on AI applications in the pharmaceutical field, particularly in rehabilitation robots and security [1] Company Summary - Hangzhou Longde Intelligent Technology Co., Ltd. is a controlling subsidiary of Erkang Pharmaceutical, primarily engaged in the research and development of AI application software in the medical field [1] - The company has obtained operating qualifications for second-class medical devices, including medical electronic instruments, physical therapy and rehabilitation equipment, and traditional Chinese medicine instruments [1] - As of the third quarter of 2025, the company has completed the writing of documents for 3 new software copyrights and 2 invention patents, with one invention patent application having received a preliminary examination approval notice [1] Industry Summary - The focus on AI technology applications in the medical field indicates a growing trend towards integrating advanced technology in healthcare, particularly in rehabilitation and security sectors [1] - The ongoing research and development phase suggests that the company is investing heavily in innovation, which may enhance its competitive edge in the medical technology market [1]

Core Viewpoint - The company has shown positive operational performance in the first three quarters of 2025, with significant growth in both revenue and profit, setting a solid foundation for achieving annual business goals [1] Financial Performance - The company achieved operating revenue of 1.006 billion yuan, representing a year-on-year increase of 17.81% [1] - The net profit reached 39.5759 million yuan, marking a turnaround from loss to profit [1] Overseas Expansion - In July 2025, the company approved a $10 million investment through its subsidiary, Erkang Tanzania Co., Ltd., for a comprehensive formulation production project [1] - The project is progressing as planned, with purification engineering and equipment installation underway, expected to complete equipment debugging by Q4 2025, and aims to meet GMP certification conditions [1] - The company is also preparing registration materials for drug approval in compliance with Tanzanian regulatory requirements [1] Technological Development - The company's subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., is focusing on AI technology applications, particularly in rehabilitation robots and security [1] - The subsidiary has obtained operating qualifications for second-class medical devices, supporting the marketization of related businesses [1] Intellectual Property - The subsidiary has completed the writing of documents for 3 new software copyrights and 2 invention patents, with one patent application receiving initial approval [2] - This enhances the company's intellectual property protection system and accumulates core resources to improve business technical barriers and market competitiveness [2] New Project Initiatives - The company announced plans to invest $8 million in a new injection production project in Nigeria, with an estimated construction period of 18 months [2] - This investment aligns with the company's overall development strategy and aims to expand its business reach and better meet overseas customer demands, potentially becoming a new profit growth point [2]

Core Viewpoint - Erkang Pharmaceutical is a leading enterprise in the pharmaceutical excipients industry in China, with a comprehensive industry chain advantage and strong product quality and market share [1] Group 1: Business Performance - In Q3 2025, Erkang Pharmaceutical reported a revenue of 1.006 billion yuan, ranking 18th among 47 companies in the industry, significantly lower than the top company, Puluo Pharmaceutical, which had a revenue of 7.764 billion yuan [2] - The main business composition includes pharmaceutical excipients, which accounted for 246 million yuan, representing 36.29% of total revenue [2] - The net profit for the same period was 27.11 million yuan, ranking 32nd in the industry, and was substantially lower than the leading company, Zhejiang Pharmaceutical, which reported a net profit of 867 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the debt-to-asset ratio for Erkang Pharmaceutical was 15.20%, an increase from 12.90% in the previous year, and lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 27.37%, down from 30.94% year-on-year, and below the industry average of 35.38%, suggesting a need for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 14.88% to 49,100, while the average number of circulating A-shares held per shareholder decreased by 12.95% to 29,000 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fifth largest, holding 25.8786 million shares, an increase of 4.3188 million shares from the previous period [5] Group 4: Executive Compensation - The chairman, Shuai Fangwen, received a salary of 512,900 yuan in 2024, a slight increase from 512,600 yuan in 2023 [4] - The general manager, Sun Qingrong, saw a significant salary increase to 1.0148 million yuan in 2024 from 335,700 yuan in 2023, reflecting a rise of 679,100 yuan [4]